MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0109298673342421241126060049

Медицинская библиотека · Current medicinal chemistry · 2026

Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health.

Sattari Mahboobe, Panahi Ghodratollah, Shahaboddin Mohammad Esmaeil, Sattari Mohadese, Amiri Siavash, Taheri Maryam Akhavan, Karimpour Amin, Amri Jamal

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The high incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) as a hepatic component of metabolic syndrome is attributed to the ongoing rise in obesity rates. Given the beneficial effects of hydroxychloroquine (HCQ) on metabolism, there is growing interest in combining it with fisetin (FSN), a natural product, to treat NAFLD more effectively.

OBJECTIVE

The efficacy and safety of the combined therapy of FSN and HCQ in animal models of NAFLD were assessed, focusing on liver function, insulin sensitivity, oxidative stress, and inflammation.

MATERIALS AND

METHODS

C57BL/6J mice were fed either a standard chow diet or a high-- fat diet to induce NAFLD. FSN and HCQ were administered to the mice, and biochemical parameters related to glucose and lipid metabolism, as well as oxidative stress markers, were measured in serum and liver tissue. Analyses included Oil Red O staining, mRNA levels of key lipid metabolism molecules, and immunohistochemical assessments of macrophage infiltration. Statistical analyses were performed using GraphPad Prism 9.

RESULTS

While the HCQ group exhibited some improvements in certain markers, it also displayed adverse effects. The FSN group, particularly the FSN + HCQ group, effectively reversed insulin sensitivity, glucose homeostasis, and NAFLD markers by modulating lipid metabolism and inflammation pathways. HCQ exacerbated oxidative stress, which was mitigated by the effects of FSN.

CONCLUSION

Despite concerns regarding the long-term side effects of HCQ, its combination with FSN presents a promising approach for improving the management of NAFLD by reducing risks and enhancing outcomes.

Для цитирования: Sattari Mahboobe, Panahi Ghodratollah, Shahaboddin Mohammad Esmaeil, Sattari Mohadese, Amiri Siavash, Taheri Maryam Akhavan, Karimpour Amin, Amri Jamal. Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health.. Current medicinal chemistry. 2026. DOI: 10.2174/0109298673342421241126060049.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.